Key result
Compound A-52 significantly lowers blood pressure in rat models of adrenaline-induced hypertension.
Why the study?
Hypertension is closely associated with disturbances in calcium ion homeostasis in vascular and cardiac tissues, prompting this exploration of the antihypertensive activity and calcium-regulatory actions of compound A-52.
Does intravenous compound A-52 reduce systolic and diastolic blood pressure in Wistar rats with adrenaline-induced acute hypertension?
Does intravenous compound A-52 reduce systolic and diastolic blood pressure in Wistar rats with adrenaline-induced acute hypertension?
Answers are grounded in this paper and cite their sources.
Compound A-52 demonstrates preliminary antihypertensive activity in an acute rat model of hypertension at 25 mg/kg and moderate in silico binding affinity across multiple calcium-regulatory proteins.
Hypertension is closely associated with disturbances in calcium ion (Ca²⁺) homeostasis in vascular and cardiac tissues. In this study, the antihypertensive activity of compound A-52 was explored using combined in silico and in vivo approaches. Molecular docking analysis was conducted to assess the interaction of A-52 with selected Ca²⁺-related targets, including L-type and R-type calcium channels, SERCA (Ca²⁺-ATPase), RyR2 (ryanodine receptor), the Na⁺/Ca²⁺ exchanger (NCX), and renin. The docking results revealed moderate binding affinities (–5.2 to –6.1 kcal/mol), which are commonly observed in preliminary docking studies, with interactions mediated by hydrogen bonding, π–π stacking, and hydrophobic contacts with key amino acid residues. These in silico findings, together with vascular reactivity data, suggest a possible involvement of calcium-dependent mechanisms, although no direct electrophysiological or Ca²⁺ flux measurements were performed. The in vivo antihypertensive effect of A-52 was evaluated in an adrenaline-induced acute hypertension model in Wistar rats. Intravenous administration of A-52 at a dose of 25 mg/kg resulted in a significant reduction of systolic and diastolic blood pressure within two hours, without evidence of severe hypotension. In contrast, a higher dose (50 mg/kg) induced a transient and unstable blood pressure response, indicating dose sensitivity under the applied conditions. Comparative evaluation with structurally related compounds (A-51 and A-54) showed that A-52 produced a more consistent antihypertensive response in this acute model. Overall, the results provide preliminary evidence that A-52 may influence pathways associated with Ca²⁺ handling and blood pressure regulation. Further studies involving chronic models, larger sample sizes, pharmacokinetic profiling, toxicity assessment, and direct functional assays are required to clarify its mechanism of action and therapeutic relevance. HIGHLIGHTS Compound A-52 was evaluated for antihypertensive activity using in silico and in vivo approaches. Molecular docking predicted interactions of A-52 with multiple Ca²⁺-regulating proteins. A-52 exhibited docking affinities ranging from −5.2 to −6.1 kcal/mol across the investigated targets. A-52 at 25 mg/kg reduced systolic and diastolic blood pressure in hypertensive rats. The findings suggest potential calcium-dependent mechanisms underlying A-52 activity, warranting further validation.
No takes yet. Share an insight, caveat, or question.
Sayidaliyeva et al. (2026) studied Adrenaline-induced acute hypertension (n=12). Compound A-52 (3,4,5-trimethoxy-4-hydroxybenzoic acid methyl ester) vs. Untreated adrenaline-only control, A-51 (25 mg/kg), and A-54 (25 mg/kg) was evaluated on Systolic blood pressure (SBP) at 2 hours post-administration (p=<0.05). Compound A-52 reduced systolic blood pressure to 103.3 mmHg and diastolic blood pressure to 69.3 mmHg at 2 hours in rats with adrenaline-induced hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: